Close

Mylan (MYL) Reports Herceptin Settlement and License Agreement with Genentech and Roche

Go back to Mylan (MYL) Reports Herceptin Settlement and License Agreement with Genentech and Roche

Mylan Announces Global Settlement and License Agreements with Genentech and Roche on Herceptin®

March 13, 2017 8:00 AM EDT

HERTFORDSHIRE, England and PITTSBURGH, March 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. in relation to patents for Herceptin® (trastuzumab), which provides Mylan with global licenses for its trastuzumab product.

The global license will provide a clear pathway for Mylan to commercialize its trastuzumab product in various markets around the world, commencing on the license effective dates,... More